Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma

a case report

Yaoru Huang, Shang Wen Chen, Chia-chun Kuo, Jeng-Fong Chiou

Research output: Contribution to journalArticle

Abstract

In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.
Original languageEnglish
Pages (from-to)155-158
JournalCase Reports in Clinical Pathology
Volume1
Issue number2
Publication statusPublished - 2014

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Therapeutic Uses
Portal Vein
Tumor Burden
Neoplasms
Thrombosis
sorafenib
Therapeutics
Clinical Studies

Keywords

  • Hepatocellular carcinoma
  • Radiation therapy
  • Sorafenib

Cite this

Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma : a case report . / Huang, Yaoru; Chen, Shang Wen; Kuo, Chia-chun; Chiou, Jeng-Fong.

In: Case Reports in Clinical Pathology, Vol. 1, No. 2, 2014, p. 155-158.

Research output: Contribution to journalArticle

@article{ba53edd8a5ce4ff9b4693d4a1e1a350e,
title = "Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma: a case report",
abstract = "In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.",
keywords = "Hepatocellular carcinoma, Radiation therapy, Sorafenib",
author = "Yaoru Huang and Chen, {Shang Wen} and Chia-chun Kuo and Jeng-Fong Chiou",
year = "2014",
language = "English",
volume = "1",
pages = "155--158",
journal = "Case Reports in Clinical Pathology",
number = "2",

}

TY - JOUR

T1 - Combination of radiotherapy and sorafenib in recurrent hepatocellular carcinoma

T2 - a case report

AU - Huang, Yaoru

AU - Chen, Shang Wen

AU - Kuo, Chia-chun

AU - Chiou, Jeng-Fong

PY - 2014

Y1 - 2014

N2 - In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.

AB - In patients with unresectable hepatocellular carcinoma (HCC), radiotherapy is considered for patients with a large tumor burden or tumors with portal vein tumor thrombosis, which is not indicated for operation or transarterial chemoembolization. Sorafenib has proved to be effective as a first-line treatment for locally advanced and metastatic HCC. Preclinical and clinical studies have shown the efficacy of the combined therapeutic effects of radiotherapy (RT) with sorafenib used either concurrently or sequentially. We presented a patient with multiple recurrent HCCs successfully treated with combined RT and sorafenib.

KW - Hepatocellular carcinoma

KW - Radiation therapy

KW - Sorafenib

M3 - Article

VL - 1

SP - 155

EP - 158

JO - Case Reports in Clinical Pathology

JF - Case Reports in Clinical Pathology

IS - 2

ER -